HUYA Bioscience signs collaboration deal with TechCode Gu’an Life Sciences Park

The collaboration will focus on promoting the development of biomedical innovations from companies located in the park that could help meet the growing demand to fill global pharmaceutical pipelines.

HUYA is the first company to have recognized China’s potential as an important source of new innovative preclinical and clinical stage compounds. The company accelerates the development and value creation for China-sourced novel biopharmaceutical compounds in worldwide markets.

HUYA has already established over one hundred collaborations with leading universities and research institutes throughout China as a pioneer in licensing of both preclinical and clinical stage compounds.

TechCode Gu’an Life Sciences Park is operated by TechCode SME Services Co., Ltd., which focuses on incubator operation management and technology startup cultivation and is committed to building the world’s leading entrepreneurship ecosystem. TechCode Gu’an Park is located in China’s Hebei Province, close to the capital Beijing and with unique geographical advantages.

The park has chosen biological products as its core area, positioning itself to be a base of biomedical translational medicine and targeting innovative R&D for a breakthrough in the high-end part of the industry value chain. Its objective is to enhance the connection between research and clinical studies and to promote the development and commercialization of innovative drugs.

Under this partnership, HUYA and TechCode Gu’an Park will work together to promote the development of innovative drugs from the local area that have global market potential. Biotech and pharmaceutical companies in TechCode Gu’an Park will have access to HUYA’s international pharmaceutical knowledge and networks as well as the company’s team of experts in drug development and globalization.

In turn, HUYA will have priority to evaluate certain research and development projects conducted by these companies in the park and provide support and advice as needed.

HUYA’s chief technology officer and COO for Asia Clement Gingras said: "With TechCode Gu’an Park’s unique regional advantages, this collaboration further complements our strategic cooperation layout in North China. Through this cooperation, we would like to enable the development of more China-sourced novel pharmaceutical compounds.

"We feel confident of this partnership and look forward to prominent achievements in the near future."

Xinxi Si, General Manager of TechCode Healthcare and Head of Gu’an Life Sciences Park, said: "We are delighted to have HUYA as a partner. Combining TechCode Gu’an Park’s special resources and HUYA’s international expertise in novel drug development will help us increase the success rate of industrialization and create value for enterprises in our park and in the surrounding areas."